Experience of subcutaneous levetiracetam in palliative care

Gaviria-Carrillo, Mariana; Mora-Muñoz, Laura; Díaz-Forero, Andrés Felipe; Vargas-Osorio, Juliana; Torres-Ballesteros, Viviana; Estrada, Jhonatan; Vélez Van Meerbeke, Alberto; Rodriguez-Quintana, Jesús Hernán

Mostrar el registro sencillo del documento

dc.creator	Gaviria-Carrillo, Mariana
dc.creator	Mora-Muñoz, Laura
dc.creator	Díaz-Forero, Andrés Felipe
dc.creator	Vargas-Osorio, Juliana
dc.creator	Torres-Ballesteros, Viviana
dc.creator	Estrada, Jhonatan
dc.creator	Vélez Van Meerbeke, Alberto
dc.creator	Rodriguez-Quintana, Jesús Hernán
dc.date.accessioned	2023-02-14T00:38:21Z
dc.date.available	2023-02-14T00:38:21Z
dc.date.created	2023-02
dc.identifier.issn	1011-7571	spa
dc.identifier.uri	http://repositorio.mederi.com.co/handle/123456789/745
dc.description	Background: Seizures are common in palliative care. Their control is essential in the management of these patients as it helps to reduce suffering at the end of life. Subcutaneous levetiracetam has been used off-license for seizure control in palliative care. Aim: Describe the experience of subcutaneous levetiracetam in two hospitals in Bogota, Colombia Methods: We conducted a retrospective review of patients treated with subcutaneous levetiracetam in two hospitals in Colombia during 2019-2021.Data were extracted from medical records, and participants were followed up as outpatients. Results: Twenty-one patients were identified. No severe adverse effects or a rise in ictal frequency were documented. Twelve patients died during hospitalization and nine continued treatment as outpatients. The principal diagnosis was structural focal epilepsy. The daily dose ranged from 1000 mg to 3000 mg, and the duration of treatment varied amongst subjects between 1 and up to 360 days. Conclusion: In our experience, subcutaneous levetiracetam was well-tolerated and effective in controlling seizures in palliative care when oral administration or intravenous access was not an option. Randomized controlled trials are needed to elucidate the efficacy and tolerability of subcutaneous levetiracetam in clinical practice.	spa
dc.format.mimetype	application/pdf	spa
dc.relation.uri	https://doi.org/10.1159/000529461	spa
dc.rights	Atribución-NoComercial-SinDerivadas 2.5 Colombia	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/2.5/co/	*
dc.title	Experience of subcutaneous levetiracetam in palliative care	spa
dc.subject.keyword	levetiracetam	spa
dc.subject.keyword	palliative care	spa
dc.rights.accessRights	openAccess	spa
dc.type.hasVersion	acceptedVersion	spa

Archivos en el documento

Archivos	Tamaño	Formato	Ver
No hay archivos asociados a este documento.

Este documento aparece en la(s) siguiente(s) colección(ones)

Investigación clínica [389]

Mostrar el registro sencillo del documento

Excepto si se señala otra cosa, la licencia del documento se describe como Atribución-NoComercial-SinDerivadas 2.5 Colombia